Phreesia (PHR) to Release Quarterly Earnings on Thursday

Key Points

• Phreesia is set to announce its Q2 2026 earnings on September 4th, with analysts predicting a loss of ($0.07) per share and revenues of $116.39 million.
• In its last earnings report, Phreesia exceeded expectations, reporting a loss of ($0.07) per share, better than the estimated ($0.13), and revenues of $115.94 million.
• The stock has received multiple upgrades, including a "strong-buy" rating from DA Davidson and a raised price target from Truist Financial to $35.00.

Phreesia (NYSE:PHR - Get Free Report) is anticipated to post its Q2 2026 results after the market closes on Thursday, September 4th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $116.39 million for the quarter. Parties are encouraged to explore the company's upcoming Q2 2026 earningoverview page for the latest details on the call scheduled for Thursday, September 4, 2025 at 5:00 PM ET.

Phreesia (NYSE:PHR - Get Free Report) last released its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company had revenue of $115.94 million during the quarter, compared to the consensus estimate of $115.00 million. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%.Phreesia's revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.05) EPS. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Price Performance

PHR stock opened at $32.00 on Thursday. The business has a 50 day moving average price of $27.81 and a 200 day moving average price of $26.47. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -43.25 and a beta of 0.71. Phreesia has a fifty-two week low of $17.07 and a fifty-two week high of $32.13. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.02.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PHR shares. DA Davidson raised Phreesia to a "strong-buy" rating in a report on Tuesday, July 22nd. Truist Financial raised their price objective on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Mizuho initiated coverage on Phreesia in a research note on Wednesday. They issued an "outperform" rating and a $36.00 target price for the company. Wall Street Zen upgraded Phreesia from a "hold" rating to a "buy" rating in a research report on Sunday, June 1st. Finally, Citigroup reissued a "buy" rating on shares of Phreesia in a report on Wednesday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the company. According to MarketBeat.com, Phreesia presently has a consensus rating of "Buy" and an average price target of $32.58.

Insider Buying and Selling

In other news, General Counsel Allison C. Hoffman sold 1,245 shares of the company's stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $26.89, for a total value of $33,478.05. Following the sale, the general counsel directly owned 136,978 shares in the company, valued at approximately $3,683,338.42. This represents a 0.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider David Linetsky sold 17,445 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $29.73, for a total value of $518,639.85. Following the transaction, the insider directly owned 174,002 shares in the company, valued at approximately $5,173,079.46. This represents a 9.11% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 71,327 shares of company stock valued at $2,031,647. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its position in Phreesia by 0.4% during the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company's stock valued at $15,336,000 after purchasing an additional 2,402 shares in the last quarter. Bank of America Corp DE boosted its position in Phreesia by 6.2% during the second quarter. Bank of America Corp DE now owns 539,368 shares of the company's stock valued at $15,350,000 after acquiring an additional 31,706 shares during the last quarter. Qube Research & Technologies Ltd boosted its position in Phreesia by 156.1% during the second quarter. Qube Research & Technologies Ltd now owns 389,519 shares of the company's stock valued at $11,086,000 after acquiring an additional 237,394 shares during the last quarter. Sei Investments Co. boosted its position in Phreesia by 23.2% during the second quarter. Sei Investments Co. now owns 242,709 shares of the company's stock valued at $6,907,000 after acquiring an additional 45,772 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Phreesia by 17.5% during the 2nd quarter. AQR Capital Management LLC now owns 188,089 shares of the company's stock worth $5,353,000 after purchasing an additional 28,057 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.